Fox Run Management L.L.C. Buys New Shares in Bio-Rad Laboratories, Inc. (NYSE:BIO)

Fox Run Management L.L.C. bought a new stake in shares of Bio-Rad Laboratories, Inc. (NYSE:BIO) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm bought 3,122 shares of the medical research company’s stock, valued at approximately $1,026,000.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Strategic Financial Concepts LLC bought a new stake in Bio-Rad Laboratories in the 4th quarter worth $3,561,000. Lecap Asset Management Ltd. bought a new stake in Bio-Rad Laboratories in the 4th quarter worth $510,000. Verition Fund Management LLC grew its holdings in Bio-Rad Laboratories by 193.3% in the 3rd quarter. Verition Fund Management LLC now owns 3,470 shares of the medical research company’s stock worth $1,161,000 after acquiring an additional 2,287 shares during the last quarter. Diversified Trust Co bought a new stake in Bio-Rad Laboratories in the 4th quarter worth $958,000. Finally, DAVENPORT & Co LLC grew its holdings in Bio-Rad Laboratories by 48.8% in the 4th quarter. DAVENPORT & Co LLC now owns 84,677 shares of the medical research company’s stock worth $27,817,000 after acquiring an additional 27,780 shares during the last quarter. Institutional investors own 65.24% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts have issued reports on the stock. StockNews.com lowered shares of Bio-Rad Laboratories from a “buy” rating to a “hold” rating in a report on Monday, February 17th. Wells Fargo & Company cut their price target on shares of Bio-Rad Laboratories from $360.00 to $345.00 and set an “equal weight” rating on the stock in a report on Wednesday, February 12th. Finally, Royal Bank of Canada reissued an “outperform” rating and issued a $481.00 price target on shares of Bio-Rad Laboratories in a report on Tuesday, January 14th. Three analysts have rated the stock with a hold rating and three have issued a buy rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $395.20.

Bio-Rad Laboratories Trading Up 0.8 %

NYSE:BIO opened at $256.42 on Friday. The company has a 50-day moving average price of $303.23 and a 200-day moving average price of $325.28. Bio-Rad Laboratories, Inc. has a 12 month low of $244.00 and a 12 month high of $387.99. The company has a current ratio of 6.48, a quick ratio of 4.85 and a debt-to-equity ratio of 0.18. The stock has a market cap of $7.18 billion, a price-to-earnings ratio of -3.94 and a beta of 0.98.

Bio-Rad Laboratories (NYSE:BIO) last issued its quarterly earnings results on Thursday, February 13th. The medical research company reported $2.90 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.86 by $0.04. Bio-Rad Laboratories had a negative net margin of 71.86% and a positive return on equity of 3.90%. Equities analysts predict that Bio-Rad Laboratories, Inc. will post 10.81 EPS for the current year.

Bio-Rad Laboratories Company Profile

Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.